Slide 1: Exchange filing cover letter: Earnings Presentation
^ franced enzymes Where ENZYME is Life Advanced Enzyme Technologies Ltd. CIN: L24200MH1989PLC051018 Sun Magnetica, A wing, 5 th Floor, LIC Service Road, Louiswadi, Thane ( W ) -400 604, India Tel: + 91-22-4170 3200, Fax: + 91 -22- 2583 5159 Email: info@ advancedenzymes.com, www.advancedenzymes.com N
Slide 2: Advanced Enzyme Technologies Limited Corporate Presentation
Advanced Enzyme Technologies Limited Corporate Presentation November 2024
Slide 3: Safe Harbour Statement
Safe Harbour Statement ^ Manced enzymes Where ENZYME is Lite This presentation contains forward-looking statements that reflect management’s current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical fac
Slide 4: Result Summary Q2 FY25 and contents
/ ^ \ / ^^ u anced enzymes Where ENZYME is Life 1 2 3 Result Summary Business Geographical Q2 FY25 Performance Performance Page: 04 Page: 07 Page: 11 4 5 6 7 Result Summary Unique Focus Area Shareholders’ FY24 Investment Case Going Ahead Information Page: 12 Page: 26 Page: 30 Page: 32 Earnings Prese
Slide 5: Results Summary – Q2 FY25 (Consolidated) Y-o-Y
Results Summary – Q2 FY25 (Consolidated) Y-o-Y ^ Manced enzymes Where ENZYME is Lite Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,578 513 352 1,461 I 334 424 07% 17% 05% Q2 FY24 Q2 FY25 Q2 FY24 Q2 FY25 Q2 FY24 Q2 FY25 Revenue de-grew by 7% on y-o-y basis to EBITDA de-grew by 17% to ₹ 424 million in Q2
Slide 6: Results Summary – Q2 FY25 (Consolidated) Q-o-Q
Results Summary – Q2 FY25 (Consolidated) Q-o-Q ^ Manced enzymes Where ENZYME is Lite Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 350 I 1,545 334 1,461 512 I 05% 17% 424 05% Q1 FY25 Q2 FY25 Q1 FY25 Q2 FY25 Q1 FY25 Q2 FY25 Revenue de-grew by 5% on q-o-q basis to ₹ 1,461 million in Q2 EBITDA de-grew by 17%
Slide 7: Results Summary – H1 FY25 (Consolidated) Y-o-Y
Results Summary – H1 FY25 (Consolidated) Y-o-Y ^ Manced enzymes Where ENZYME is Lite Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 3,051 3,006 953 936 684 646 01% 02% 06% H1 FY24 H1 FY25 H1 FY24 H1 FY25 H1 FY24 H1 FY25 Revenue de-grew by 1% on y-o-y basis to EBITDA de-grew by 2% to ₹ 936 million in the PA
Slide 8: Human Nutrition
Human Nutrition \nced enzymes Where ENZYME is Lite (₹ in Million) 1,059 1,107 Commentary: 994 1,024 1,012 992 939 934 • The human nutrition segment contributed 877 around 68% during the quarter to the total revenue from operations • This segment de-grew by 6% during the quarter from ₹ 1,059 million
Slide 9: Animal Nutrition
Animal Nutrition (₹ in Million) Commentary: ^ Manced enzymes Where ENZYME is Lite 206 • The animal nutrition segment contributed 185 181 around 12% during the quarter to the total 172 175 173 172 158 162 revenue from operations • This segment grew by 5% during the quarter from ₹ 173 million in Q2 FY
Slide 10: Industrial Bio-processing
Industrial Bio-processing (₹ in Million) Commentary: ^ Mancecl enzymes Where ENZYME is Lite 258 • The Industrial Bio-Processing segment contributed about 243 251 12% during the quarter to the total revenue from 236 226 224 operations • This segment de-grew by 31% on y-o-y basis to ₹ 168 193 192 mill
Slide 11: Specialized Manufacturing
Specialized Manufacturing (₹ in Million) Commentary: ^ Mancecl enzymes Where ENZYME is Lite 120 113 111 110 • This segment contributed about 8% during the 103 104 quarter to the total revenue from operations 97 which was 7% during the same quarter last 83 86 year • This segment grew by 17% on y-o-y
Slide 12: Geographical performance
Geographical performance ^ Mancecl enzymes Where ENZYME is Lite ¥ W y - Mr wt (₹ in Million) Rest of the India Americas Europe Asia* World 48% 39% 04% 07% 02% Q2 FY25 -15% +21% -35% -25% -49% Q2 FY25 703 Q2 FY25 571 Q2 FY25 54 Q2 FY25 101 Q2 FY25 32 Q2 FY24 828 Q2 FY24 470 Q2 FY24 83 Q2 FY24 135 Q2
Slide 13: Profit & Loss (Consolidated) – Q2 & H1 FY25
Profit & Loss (Consolidated) – Q2 & H1 FY25 ^ Manced enzymes Where ENZYME is Lite (₹ in Million) Q2 FY25 Q1 FY25 Q2 FY24 Y-o-Y Q-o-Q H1 FY25 H1 FY24 Particulars Y-o-Y (%) Un-Audited Un-Audited Un-Audited (%) (%) Un-Audited Un-Audited Income from Operations 1,461 1,545 1,578 -7% -5% 3,006 3,051 -1% E
Slide 14: Balance Sheet (Consolidated) – H1 FY25
Balance Sheet (Consolidated) – H1 FY25 ^ Manced enzymes Where ENZYME is Lite (₹ in Million) H1 FY25 H1 FY24 H1 FY23 Particulars Un-Audited Un-Audited Un-Audited Assets Property, plant and equipment 2,811 2,734 2,623 Capital work-in-progress 453 220 213 Intangible assets 449 512 559 Goodwill 3,278 3,
Slide 15: Result summary - FY24 (Consolidated) Y-o-Y
Result summary - FY24 (Consolidated) Y-o-Y ^ Mancecl enzymes Where ENZYME is Life (₹ in Million) Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 0A 6,239 2,045 1,370 5,406 1,564 1,039 1 1 1 FY23 FY24 FY23 FY24 FY23 FY24 Human Nutrition Animal Nutrition Bio Processing Specialized Manufacturing +18% -5% +21%
Slide 16: Revenue Mix – FY24 vs. FY23
Revenue Mix – FY24 vs. FY23 FY24 ^ Mancecl enzymes Where ENZYME is Lite 3% 7% 7% 15% 6% 50% 11% 67% 34% Human Nutrition Animal Nutrition Bio-Processing Specialised Manufacturing India Americas Europe Asia (ex-India) Rest of the World FY23 2% 6% 9% 15% 7% 47% 13% 35% 66% Human Nutrition Animal Nutrit
Slide 17: Strong Financial Performance – FY24
Strong Financial Performance – FY24 Revenue from Operations EBIDTA & EBIDTA Margin (%) ^ Manced enzymes Where ENZYME is Lite (₹ in Million) 6,239 2,500 46% 46% 50% 5,294 5,406 38% 45% 5,018 4,440 2,000 40% 29% 33% 35% 1,500 30% 25% 1,000 20% 15% 500 10% 2,023 2,316 2,014 1,564 2,045 5% 0 0% FY 20 FY
Slide 18: Strong Financial Performance – FY24
Strong Financial Performance – FY24 Net Working Capital (Days) Net Worth (₹ mn) ^ Manced enzymes Where ENZYME is Lite 13,241 135 135 12,351 132 10,886 9,709 8,397 120 115 FY 20 FY 21 FY 22 FY 23 FY 24 FY 20 FY 21 FY 22 FY 23 FY 24 ROE (%) & ROCE (%) Net Debt to Equity (x) 22.44% 21.94% 0.02 0.02 0.0
Slide 19: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) ^ Manced enzymes Where ENZYME is Lite (₹ in Million) FY24 FY23 FY22 Particulars Audited Audited Audited Assets Property, plant and equipment 2,765 2,732 2,622 Capital work-in-progress 411 215 151 Intangible assets 479 550 609 Goodwill 3,253 3,209 2,961 Other non-current
Slide 20: Annexure
Annexure
Slide 21: Company Overview, Mission and Vision
Company Overview Advanced enzvmt Where ENZYME is Life What are Probiotics? Advanced Enzymes is a research driven company with global Probiotics are live microorganisms, when administered in sufficient amount, leadership in the manufacturing of enzymes and probiotics. confer health benefits to human
Slide 22: A Rising Global Star
Advanced Enzyme Technologies Limited – A Rising Global Star Priced enzymes Where ENZYME is Lite 9 68+ 400+ 700+ Manufacturing Units India – 8 | USA - 1 7 Enzymes & Probiotics Proprietary Products © Customers Worldwide O ITS R&D Units India – 5 | USA – 1 | 45+ 750+ 13* 1st Indian Enzyme gpi Wms~£ Ger
Slide 23: Brief History and Evolution
Brief History and Evolution ^ ifrancecl enzymes Where ENZYME is Lite • Equity investment • 4 food enzymes got by Kotak Private approved as a Equity processing aid with • Takeover of Food Safety Standard • Received NIH grant for • Received approval for 2 Advanced Authority of India ImmunoSEB and food
Slide 24: Board of Directors
Board of Directors Advanced enzymes Where ENZYME is Life Mr. Vasant Rathi Mr. Mukund M. Kabra Mr. Pramod Kasat Promoter Chairman and Non-Executive Director Whole-time Director Independent Director Ms. Rasika Rathi Mr. Vinod Jajoo Mr. Sunny Sharma Non-Executive Director Independent Director Non-Execu
Slide 25: Management Team
Management Team ^ Mancecl enzymes Where ENZYME is Life ' El m Mr. Beni Prasad Rauka Mr. Dipak Roda Mr. Harshad Doshi Ms. Martina Doering Group Chief Financial Officer Vice President / Market & Business CFO & COO - Advanced Enzymes, USA Managing Director /Head Of Business Development Development - ev
Slide 26: How Big is the Opportunity?
How Big is the Opportunity? Global Enzymes Market ^ Manced enzymes Where ENZYME is Lite Global Probiotics Market Grow at a $6Bn 8% Grow at a CAGR 7.75% CAGR 6% $11.3Bn CY 2023-28 till 2030 $7Bn $923Mn 11% $57Bn $400Mn 81% $70Bn $1.85Bn $3.57Bn $250Mn $500Mn $800Mn Animal Feed Dietary Supplements Fun
Slide 27: What Makes AETL a Unique Investment Case?
What Makes AETL a Unique Investment Case? ^ Mancecl enzymes Where ENZYME is Lite Specialized Business with High Entry Barriers a Strong Research & Development Capabilities ¥ Integrated Player with Presence Across the Enzyme Value Chain <sjb Inherent Diversification in the Business Model Significant
Slide 28: Integrated Player with Presence Across the Enzyme Value Chain
Integrated Player with Presence Across the Enzyme Value Chain Advanced enzymes Where ENZYME is Life Research & Development Manufacturing Marketing & Distribution Earnings Presentation | November 2024 27
Slide 29: What we are Aiming in the Opportunity?
What we are Aiming in the Opportunity? \nced enzymes Where ENZYME is Lite Addressable market for AETL over next 5 AETL’s Current Share of Revenue Focus Area Opportunity Size years** FY24 FY23 Human Nutrition $ 400 mn $ 200 mn $ 43.5 mn, 58% $ 38.8 mn, 58% Bio-Catalysis $ 60 mn $ 30 mn* $ 3.3 mn, 4%
Slide 30: Specialized Business With High Entry Barriers
Specialized Business With High Entry Barriers Technocrat Global Promoters Competitiveness Amongst the Lowest Cost Cumulative experience of 7+ decades Manufacturers in the World in the global enzyme industry (Benchmarked both in terms of Capex & Opex) Sustained Research Diverse Product Range & Develo
Slide 31: Future Growth Drivers
Future Growth Drivers ^ Mancecl enzymes Where ENZYME is Lite Continued Broaden & Deepen Inorganic Investment in R&D Geographical Presence Expansion o Acquisition of Key Technologies, Competencies & o Identify Product gaps and Develop new Enzymes, o Increased focus on high return applications where S
Slide 32: Focus Areas Going Ahead
Focus Areas Going Ahead ^ Manced enzymes Where ENZYME is Lite • Continuing conduct trials and studies to bring newer and effective nutritional products, which may improve the efficacy of animal feeds • Registering and introducing more products in the domestic as well as in the international markets.
Slide 33: Shareholders Information
Shareholders Information Stock Data (As on 8th Nov 2024) Top Institutional Holders (As on 3rd Nov 2024) ^ Mancecl enzymes Where ENZYME is Lite Institutions OS (%) Market Capitalization (₹) 53,825 mn ORBIMED ASIA III MAURITIUS 12.07 NALANDA INDIA EQUITY FUND 8.46 9 Shares Outstanding 111.88 mn HDFC M
Slide 34: Thank you
^^ ancec! enzymes Where ENZYME is Life titute - AWS, sawant Chowk Nitin Thank you google Cloud Co.. I / / U E| [ Pipe /fne s Square k ^ Advanced Enzyme Dnyaneshwar Sun Crest Chowk Technologies o% te °o% : Prashant Corner Advanced Enzyme Technologies Limited Darg IRTicTgipfc Address: 5th Floor, 'A' w